Diabetes & Metabolism Journal

Original Articles

Others
Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis: Ji Soo Kim, Gyeongsil Lee, Kyung-Il Park, Seung-Won Oh; Diabetes Metab J. 2024;48(2):312-320. Published online January 26, 2024; DOI: https://doi.org/10.4093/dmj.2022.0421

1,211 View
202 Download
1 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
There is still a lack of research on which diabetic drugs are more effective in preventing stroke. Our network metaanalysis aimed to compare cerebrovascular benefits among glucose-lowering treatments.
Methods
We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov registry for clinical trials from inception through May 25, 2021. We included both prespecified cerebrovascular outcomes and cerebrovascular events reported as severe adverse events. Subgroup analyses were conducted by stroke subtype, publication type, age of patients, baseline glycosylated hemoglobin (HbA1c), duration of type 2 diabetes mellitus, and cardiovascular risks.
Results
Of 2,861 reports and 1,779 trials screened, 79 randomized controlled trials comprising 206,387 patients fulfilled the inclusion criteria. In the pairwise meta-analysis, the use of glucagon-like peptide-1 (GLP-1) agonist was associated with a lower risk of total stroke compared with placebo (relative risk [RR], –0.17; 95% confidence interval [CI], –0.27 to –0.07). In the network meta- analysis, only the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitor was associated with a reduction of total stroke, compared with placebo (RR, 0.81; 95% CI, 0.67 to 0.98). In the subgroup analyses, the use of SGLT-2 inhibitor and GLP-1 agonist was associated with a lower risk of stroke in those with high HbA1c (≥8.0) and low-risk of cardiovascular disease, respectively.
Conclusion
SGLT-2 inhibitors and GLP-1 agonists were shown to be beneficial for stroke prevention in patients with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes
Jae-Han Jeon
Diabetes & Metabolism Journal.2024; 48(2): 213. CrossRef
Reply to comment on: Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyser database
Wolfgang Rathmann, Karel Kostev
Acta Diabetologica.2024;[Epub] CrossRef

Cardiovascular Risk/Epidemiology
Psychotic Disorders and the Risk of Type 2 Diabetes Mellitus, Atherosclerotic Cardiovascular Diseases, and All-Cause Mortality: A Population-Based Matched Cohort Study: You-Bin Lee, Hyewon Kim, Jungkuk Lee, Dongwoo Kang, Gyuri Kim, Sang-Man Jin, Jae Hyeon Kim, Hong Jin Jeon, Kyu Yeon Hur; Diabetes Metab J. 2024;48(1):122-133. Published online January 3, 2024; DOI: https://doi.org/10.4093/dmj.2022.0431

1,089 View
144 Download

Abstract PDF Supplementary Material PubReader ePub: Background
The effects of psychotic disorders on cardiometabolic diseases and premature death need to be determined in Asian populations.
Methods
In this population-based matched cohort study, the Korean National Health Insurance Service database (2002 to 2018) was used. The risk of type 2 diabetes mellitus (T2DM), acute myocardial infarction (AMI), ischemic stroke, composite of all cardiometabolic diseases, and all-cause death during follow-up was compared between individuals with psychotic disorders treated with antipsychotics (n=48,162) and 1:1 matched controls without psychiatric disorders among adults without cardiometabolic diseases before or within 3 months after baseline.
Results
In this cohort, 53,683 composite cases of all cardiometabolic diseases (during median 7.38 years), 899 AMI, and 1,216 ischemic stroke cases (during median 14.14 years), 7,686 T2DM cases (during median 13.26 years), and 7,092 deaths (during median 14.23 years) occurred. The risk of all outcomes was higher in subjects with psychotic disorders than matched controls (adjusted hazard ratios [95% confidence intervals]: 1.522 [1.446 to 1.602] for T2DM; 1.455 [1.251 to 1.693] for AMI; 1.568 [1.373 to 1.790] for ischemic stroke; 1.595 [1.565 to 1.626] for composite of all cardiometabolic diseases; and 2.747 [2.599 to 2.904] for all-cause mortality) during follow-up. Similar patterns of associations were maintained in subgroup analyses but more prominent in younger individuals (P for interaction <0.0001) when categorized as those aged 18–39, 40–64, or ≥65 years.
Conclusion
Patients with psychotic disorders treated with antipsychotics were associated with increased risk of premature allcause mortality and cardiometabolic outcomes in an Asian population. This relationship was more pronounced in younger individuals, especially aged 18 to 39 years.

Cardiovascular Risk/Epidemiology
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus: Seung Eun Lee, Hyewon Nam, Han Seok Choi, Hoseob Kim, Dae-Sung Kyoung, Kyoung-Ah Kim; Diabetes Metab J. 2022;46(4):567-577. Published online February 8, 2022; DOI: https://doi.org/10.4093/dmj.2021.0160

5,419 View
358 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Although cardiovascular outcome trials using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) showed a reduction in risk of 3-point major adverse cardiovascular events (MACE), they did not demonstrate beneficial effects on stroke risk. Additionally, meta-analysis showed SGLT-2i potentially had an adverse effect on stroke risk. Contrarily, pioglitazone, a type of thiazolidinedione (TZD), has been shown to reduce recurrent stroke risk. Thus, we aimed to compare the effect of SGLT-2i and TZD on the risk of stroke in type 2 diabetes mellitus (T2DM) patients.
Methods
Using the Korean National Health Insurance Service data, we compared a 1:1 propensity score-matched cohort of patients who used SGLT-2i or TZD from January 2014 to December 2018. The primary outcome was stroke. The secondary outcomes were myocardial infarction (MI), cardiovascular death, 3-point MACE, and heart failure (HF).
Results
After propensity-matching, each group included 56,794 patients. Baseline characteristics were well balanced. During the follow-up, 862 patients were newly hospitalized for stroke. The incidence rate of stroke was 4.11 and 4.22 per 1,000 person-years for the TZD and SGLT-2i groups respectively. The hazard ratio (HR) of stroke was 1.054 (95% confidence interval [CI], 0.904 to 1.229) in the SGLT-2i group compared to the TZD group. There was no difference in the risk of MI, cardiovascular death, 3-point MACE between groups. Hospitalization for HF was significantly decreased in SGLT-2i-treated patients (HR, 0.645; 95% CI, 0.466 to 0.893). Results were consistent regardless of prior cardiovascular disease.
Conclusion
In this real-world data, the risk of stroke was comparable in T2DM patients treated with SGLT-2i or TZD.

Citations

Citations to this article as recorded by

Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
André J. Scheen
Diabetes Epidemiology and Management.2024; 13: 100179. CrossRef
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
Cardiovascular Diabetology.2023;[Epub] CrossRef
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André J. Scheen
Diabetes & Metabolism.2023; 49(5): 101474. CrossRef

Cardiovascular Risk/Epidemiology
Metabolic Syndrome Severity Score for Predicting Cardiovascular Events: A Nationwide Population-Based Study from Korea: Yo Nam Jang, Jun Hyeok Lee, Jin Sil Moon, Dae Ryong Kang, Seong Yong Park, Jerim Cho, Jang-Young Kim, Ji Hye Huh; Diabetes Metab J. 2021;45(4):569-577. Published online January 30, 2021; DOI: https://doi.org/10.4093/dmj.2020.0103

6,514 View
225 Download
14 Web of Science
15 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background
Recently, a metabolic syndrome severity score (MS score) using a dataset of the Korea National Health and Nutrition Examination Surveys has been developed. We aimed to determine whether the newly developed score is a significant predictor of cardiovascular (CV) events among the Korean population.
Methods
From the Korean National Health Insurance System, 2,541,364 (aged 40 to 59 years) subjects with no history of CV events (ischemic stroke or myocardial infarction [MI]), who underwent health examinations from 2009 to 2011 and were followed up until 2014 to 2017, were identified. Cox proportional hazard model was employed to investigate the association between MS score and CV events. Model performance of MS score for predicting CV events was compared to that of conventional metabolic syndrome diagnostic criteria (Adult Treatment Program III [ATP-III]) using the Akaike information criterion and the area under the receiver operating characteristic curve.
Results
Over a median follow-up of 6 years, 15,762 cases of CV events were reported. MS score at baseline showed a linear association with incident CV events. In the multivariable-adjusted model, the hazard ratios (95% confidence intervals) comparing the highest versus lowest quartiles of MS score were 1.48 (1.36 to 1.60) for MI and 1.89 (1.74 to 2.05) for stroke. Model fitness and performance of the MS score in predicting CV events were superior to those of ATP-III.
Conclusion
The newly developed age- and sex-specific continuous MS score for the Korean population is an independent predictor of ischemic stroke and MI in Korean middle-aged adults even after adjusting for confounding factors.

Citations

Citations to this article as recorded by

Metabolic syndrome awareness in the general Korean population: results from a nationwide survey
Hyun-Jin Kim, Mi-Seung Shin, Kyung-Hee Kim, Mi-Hyang Jung, Dong-Hyuk Cho, Ju-Hee Lee, Kwang Kon Koh
The Korean Journal of Internal Medicine.2024; 39(2): 272. CrossRef
BMI-based metabolic syndrome severity score and arterial stiffness in a cohort Chinese study
Miao Wang, Chi Wang, Maoxiang Zhao, Shouling Wu, Hao Xue, Hongbin Liu
Nutrition, Metabolism and Cardiovascular Diseases.2024;[Epub] CrossRef
Association between metabolic syndrome severity score and cardiovascular disease: results from a longitudinal cohort study on Chinese adults
Jing-jing Lin, Pin-yuan Dai, Jie Zhang, Yun-qi Guan, Wei-wei Gong, Min Yu, Le Fang, Ru-ying Hu, Qing-fang He, Na Li, Li-xin Wang, Ming-bin Liang, Jie-ming Zhong
Frontiers in Endocrinology.2024;[Epub] CrossRef
Omics biomarkers and an approach for their practical implementation to delineate health status for personalized nutrition strategies
Jaap Keijer, Xavier Escoté, Sebastià Galmés, Andreu Palou-March, Francisca Serra, Mona Adnan Aldubayan, Kristina Pigsborg, Faidon Magkos, Ella J. Baker, Philip C. Calder, Joanna Góralska, Urszula Razny, Malgorzata Malczewska-Malec, David Suñol, Mar Galofr
Critical Reviews in Food Science and Nutrition.2023; : 1. CrossRef
Development and validation of a continuous metabolic syndrome severity score in the Tehran Lipid and Glucose Study
Mohammadjavad Honarvar, Safdar Masoumi, Ladan Mehran, Davood Khalili, Atieh Amouzegar, Fereidoun Azizi
Scientific Reports.2023;[Epub] CrossRef
Associations of metabolic syndrome, its severity with cognitive impairment among hemodialysis patients
Yuqi Yang, Qian Li, Yanjun Long, Jing Yuan, Yan Zha
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
Resistin serum levels and its association with clinical profile and carotid intima-media thickness in psoriasis: a cross-sectional study
Sofia Makishi Schlenker, Sofia Inez Munhoz, André Rochinski Busanello, Matheus Guedes Sanches, Barbara Stadler Kahlow, Renato Nisihara, Thelma Larocca Skare
Anais Brasileiros de Dermatologia.2023; 98(6): 799. CrossRef
Cholecystectomy Increases the Risk of Type 2 Diabetes in the Korean Population
Ji Hye Huh, Kyong Joo Lee, Yun Kyung Cho, Shinje Moon, Yoon Jung Kim, Eun Roh, Kyung-do Han, Dong Hee Koh, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm
Annals of Surgery.2023; 278(2): e264. CrossRef
Cardiorespiratory Endurance is Associated with Metabolic Syndrome Severity in Men
V. V. Sverchkov, E. V. Bykov
Journal Biomed.2023; 19(2): 61. CrossRef
Effect of a Wearable Device–Based Physical Activity Intervention in North Korean Refugees: Pilot Randomized Controlled Trial
Ji Yoon Kim, Kyoung Jin Kim, Kyeong Jin Kim, Jimi Choi, Jinhee Seo, Jung-Been Lee, Jae Hyun Bae, Nam Hoon Kim, Hee Young Kim, Soo-Kyung Lee, Sin Gon Kim
Journal of Medical Internet Research.2023; 25: e45975. CrossRef
Independent association between age- and sex-specific metabolic syndrome severity score and cardiovascular disease and mortality
Mohammadjavad Honarvar, Ladan Mehran, Safdar Masoumi, Sadaf Agahi, Shayesteh Khalili, Fereidoun Azizi, Atieh Amouzegar
Scientific Reports.2023;[Epub] CrossRef
Optimal Low-Density Lipoprotein Cholesterol Levels in Adults Without Diabetes Mellitus: A Nationwide Population-Based Study Including More Than 4 Million Individuals From South Korea
Ji Hye Huh, Sang Wook Park, Tae-Hwa Go, Dae Ryong Kang, Sang-Hak Lee, Jang-Young Kim
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Triglyceride-Glucose Index for the Diagnosis of Metabolic Syndrome: A Cross-Sectional Study of 298,652 Individuals Receiving a Health Check-Up in China
Mingfei Jiang, Xiaoran Li, Huan Wu, Fan Su, Lei Cao, Xia Ren, Jian Hu, Grace Tatenda, Mingjia Cheng, Yufeng Wen, Hou De Zhou
International Journal of Endocrinology.2022; 2022: 1. CrossRef
Changes in body composition, body balance, metabolic parameters and eating behavior among overweight and obese women due to adherence to the Pilates exercise program
Hyun Ju Kim, Jihyun Park, Mi Ri Ha, Ye Jin Kim, Chaerin Kim, Oh Yoen Kim
Journal of Nutrition and Health.2022; 55(6): 642. CrossRef
Metabolic Syndrome Severity Score, Comparable to Serum Creatinine, Could Predict the Occurrence of End-Stage Kidney Disease in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Pil Gyu Park, Jung Yoon Pyo, Sung Soo Ahn, Jason Jungsik Song, Yong-Beom Park, Ji Hye Huh, Sang-Won Lee
Journal of Clinical Medicine.2021; 10(24): 5744. CrossRef

Drug/Regimen
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus: Ja Young Jeon, Kyoung Hwa Ha, Dae Jung Kim; Diabetes Metab J. 2021;45(4):505-514. Published online October 30, 2020; DOI: https://doi.org/10.4093/dmj.2020.0057

7,894 View
341 Download
10 Web of Science
11 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background
Using real-world data, cardiovascular safety was investigated in metformin users newly starting sodium glucose cotransporter 2 (SGLT2) inhibitors compared with other glucose-lowering drugs in Korea.
Methods
This was a retrospective observational study using the National Health Insurance Service claims database in Korea. The study period was from September 2014 to December 2016. The study included subjects who were newly prescribed SGLT2 inhibitors or other glucose-lowering drugs while on metformin monotherapy; cohort 1 was composed of new users of SGLT2 inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and cohort 2 included new users of SGLT2 inhibitors versus sulfonylureas. To balance the patient characteristics, propensity score matching was performed at a 1:1 ratio. Cardiovascular outcomes included hospitalization for heart failure (HHF), all-cause mortality, HHF plus all-cause mortality, myocardial infarction (MI), stroke, and modified major adverse cardiovascular events (MACEs).
Results
After propensity score matching, each cohort group was well balanced at baseline (21,688 pairs in cohort 1 and 20,120 pairs in cohort 2). As the second-line treatment, use of SGLT2 inhibitors was associated with a lower risk of HHF and HHF plus all-cause mortality compared with DPP-4 inhibitors. In addition, use of SGLT2 inhibitors versus sulfonylurea as add-on therapy to metformin was associated with decreased risks of HHF, all-cause mortality, HHF plus all-cause mortality, MI, stroke, and modified MACEs.
Conclusion
SGLT2 inhibitors can be a good second-line drug to reduce the incidence of cardiovascular diseases compared with DPP-4 inhibitors or sulfonylureas in people with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
International Journal of Heart Failure.2023; 5(1): 1. CrossRef
Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
Diabetes & Metabolism Journal.2023; 47(1): 10. CrossRef
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Jingqian Su, Yingsheng Luo, Shan Hu, Lu Tang, Songying Ouyang
International Journal of Molecular Sciences.2023; 24(17): 13381. CrossRef
Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes
Jui Wang, Hon-Yen Wu, Kuo-Liong Chien
Diabetes & Metabolism.2022; 48(3): 101299. CrossRef
Cardiovascular disease in patients with type 2 diabetes
Ja Young Jeon, Dae Jung Kim
Journal of Diabetes Investigation.2022; 13(4): 614. CrossRef
The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients
Israel Mazin, Fernando Chernomordik, Paul Fefer, Shlomi Matetzky, Roy Beigel
Journal of Clinical Medicine.2022; 11(7): 1904. CrossRef
Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation
Chang Hee Kwon, Ye-Jee Kim, Min-Ju Kim, Myung-Jin Cha, Min Soo Cho, Gi-Byoung Nam, Kee-Joon Choi, Jun Kim
The American Journal of Cardiology.2022; 178: 35. CrossRef
Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
Ha Young Jang, In-Wha Kim, Jung Mi Oh
Frontiers in Pharmacology.2022;[Epub] CrossRef
Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
Kyuho Kim, Sung Hee Choi
Diabetes & Metabolism Journal.2021; 45(4): 502. CrossRef
The effect of sodium‐glucose transport protein 2 inhibitors on mortality and heart failure in randomized trials versus observational studies
Jesper Krogh, Carsten Hjorthøj, Søren L. Kristensen, Christian Selmer, Steen B. Haugaard
Diabetic Medicine.2021;[Epub] CrossRef
Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies
Enrico Longato, Benedetta Maria Bonora, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini
Diabetes Research and Clinical Practice.2021; 179: 109024. CrossRef

Review

Obesity and Metabolic Syndrome
Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases: Eugene Han, Yong-ho Lee; Diabetes Metab J. 2017;41(6):430-437. Published online November 17, 2017; DOI: https://doi.org/10.4093/dmj.2017.41.6.430

4,934 View
86 Download
50 Web of Science
54 Crossref

Abstract PDF PubReader

As the number of individuals with non-alcoholic fatty liver disease (NAFLD) has increased, the influence of NAFLD on other metabolic diseases has been highlighted. Accumulating epidemiologic evidence indicates that NAFLD not only affects the liver but also increases the risk of extra-hepatic diseases such as type 2 diabetes mellitus, metabolic syndrome, dyslipidemia, hypertension, cardiovascular or cerebrovascular diseases, and chronic kidney disease. Non-alcoholic steatohepatitis, an advanced type of NAFLD, can aggravate these inter-organ relationships and lead to poorer outcomes. NAFLD induces insulin resistance and exacerbates systemic chronic inflammation and oxidative stress, which leads to organ dysfunction in extra-hepatic tissues. Although more research is needed to identify the pathophysiological mechanisms and causal relationship between NAFLD and cardiometabolic and renal diseases, screening for heart, brain, and kidney diseases, risk assessment for diabetes, and a multidisciplinary approach for managing these patients should be highly encouraged.

Citations

Citations to this article as recorded by

Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management
Jiten Vora, David Cherney, Mikhail N. Kosiborod, Jonas Spaak, Naresh Kanumilli, Kamlesh Khunti, Carolyn S. P. Lam, Michael Bachmann, Peter Fenici
Diabetes, Obesity and Metabolism.2024;[Epub] CrossRef
Relationship between Uric Acid to High Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease in Nonoverweight/Obese Patients with Type 2 Diabetes
Yuliang Cui, Zhenzhen Qu, Wenmei Hu, Haiyan Shi, Faustino R. Perez-Lopez
International Journal of Endocrinology.2023; 2023: 1. CrossRef
Emerging Role of Protein O-GlcNAcylation in Liver Metabolism: Implications for Diabetes and NAFLD
Ziyan Xie, Ting Xie, Jieying Liu, Qian Zhang, Xinhua Xiao
International Journal of Molecular Sciences.2023; 24(3): 2142. CrossRef
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
Eugene Han, Yong-ho Lee
Clinical and Molecular Hepatology.2023; 29(4): 980. CrossRef
Factores de riesgo para fibrosis hepática en pacientes diabéticos con enfermedad renal cronica terminal
Ismael Yepes Barreto, Diana Romero Florez, Jorge Coronado Daza
Revista colombiana de Gastroenterología.2023; 38(3): 278. CrossRef
Circ_0004535/miR-1827/CASP8 network involved in type 2 diabetes mellitus with nonalcoholic fatty liver disease
Min Li, Ai Zeng, Xinle Tang, Hui Xu, Wei Xiong, Yanying Guo
Scientific Reports.2023;[Epub] CrossRef
Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
Cheng-Wei Yu, Chia-Hung Chen, Yung-Chi Cheng, Wen-Che Hsieh, Tzu-Ju Hsu, Fuu-Jen Tsai, Chao-Yu Hsu
European Journal of Medical Research.2023;[Epub] CrossRef
A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome
Eun Ran Kim, Jeong Su Park, Jin Hee Kim, Ji Young Oh, In Jeong Oh, Da Hyun Choi, Yu seol Lee, I. Seul Park, SeungWon Kim, Da Hyun Lee, Jae Hee Cheon, Jin‐Woo Bae, Minyoung Lee, Jin Won Cho, In Bok An, Eun Joo Nam, Sang‐In Yang, Myung‐Shik Lee, Soo Han Bae
Hepatology.2022; 75(6): 1523. CrossRef
Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Ji-Yeon Lee, Young-eun Kim, Kyungdo Han, Eugene Han, Byung Wan Lee, Eun Seok Kang, Bong-Soo Cha, Seung-Hyun Ko, Yong-ho Lee
JAMA Network Open.2022; 5(2): e220262. CrossRef
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Yongin Cho, Yong-ho Lee
Endocrinology and Metabolism.2022; 37(1): 38. CrossRef
Fatty Liver Index is a valid predictor of non-alcoholic fatty liver disease (NAFLD) in pregnancy
Iresha Sandamali Koralegedara, Janith Niwanthaka Warnasekara, Ashani Rathnayake, Korale Gedara Dayaratne, Suneth Buddhika Agampodi
BMJ Open Gastroenterology.2022; 9(1): e000913. CrossRef
A Prediction Model of the Incidence of Nonalcoholic Fatty Liver Disease With Visceral Fatty Obesity: A General Population-Based Study
Yang Zhou, Xiangping Chai, Tuo Guo, Yuting Pu, Mengping Zeng, Aifang Zhong, Guifang Yang, Jiajia Cai
Frontiers in Public Health.2022;[Epub] CrossRef
Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity
Eugene Han, Mi Kyung Kim, Seung-Soon Im, Byoung Kuk Jang, Hye Soon Kim
Journal of Diabetes and its Complications.2022; 36(8): 108253. CrossRef
Increased Risk of NAFLD in Adults with Glomerular Hyperfiltration: An 8-Year Cohort Study Based on 147,162 Koreans
Dae-Jeong Koo, Mi Yeon Lee, Inha Jung, Sun Joon Moon, Hyemi Kwon, Eun-Jung Rhee, Cheol-Young Park, Won-Young Lee, Ki Won Oh, Se Eun Park
Journal of Personalized Medicine.2022; 12(7): 1142. CrossRef
Effects of Avocado Oil Supplementation on Insulin Sensitivity, Cognition, and Inflammatory and Oxidative Stress Markers in Different Tissues of Diet-Induced Obese Mice
Schérolin de Oliveira Marques, Alexandre Pastoris Muller, Thais Fernandes Luciano, Natália dos Santos Tramontin, Mateus da Silva Caetano, Bruno Luis da Silva Pieri, Tatiane Lima Amorim, Marcone Augusto Leal de Oliveira, Cláudio Teodoro de Souza
Nutrients.2022; 14(14): 2906. CrossRef
Relationship Between Handgrip Strength and Laboratory Values in Adolescents With Non-Alcoholic Fatty Liver Disease
Si Yeong Lee, Yong Whi Jeong, Hong Koh, Yunkoo Kang
Journal of Clinical Densitometry.2022; 25(4): 490. CrossRef
Association between non-alcoholic fatty liver disease and metabolically healthy deterioration across different body shape phenotypes at baseline and change patterns
Liu Lei, Wang Changfa, Wang Jiangang, Chen Zhiheng, Yuan Ting, Zhu Xiaoling, Deng Yuling, Wang Yaqin
Scientific Reports.2022;[Epub] CrossRef
Muscle fat contents rather than muscle mass determines nonalcoholic steatohepatitis and liver fibrosis in patients with severe obesity
Eugene Han, Mi Kyung Kim, Hye Won Lee, Seungwan Ryu, Hye Soon Kim, Byoung Kuk Jang, Youngsung Suh
Obesity.2022; 30(12): 2440. CrossRef
Prediction of decreased estimated glomerular filtration rate using liver fibrosis markers: a renal biopsy-based study
Akira Mima
Scientific Reports.2022;[Epub] CrossRef
Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease
Mehmet Kanbay, Mustafa C. Bulbul, Sidar Copur, Baris Afsar, Alan A. Sag, Dimitrie Siriopol, Masanari Kuwabara, Silvia Badarau, Adrian Covic, Alberto Ortiz
Journal of Nephrology.2021; 34(3): 649. CrossRef
Taxifolin ameliorate high-fat-diet feeding plus acute ethanol binge-induced steatohepatitis through inhibiting inflammatory caspase-1-dependent pyroptosis
Zi-Ying Zhan, Mei Wu, Yue Shang, Min Jiang, Jian Liu, Chun-Ying Qiao, Huan Ye, Yong-Ce Lin, Mei-Hua Piao, Rong-Hui Sun, Zhi-Hong Zhang, Jing-Ya Jiao, Yan-Ling Wu, Ji-Xing Nan, Li-Hua Lian
Food & Function.2021; 12(1): 362. CrossRef
Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
Diabetes & Metabolism Journal.2021; 45(5): 698. CrossRef
The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008–2011)
Hyun Min Kim, Yong-ho Lee
Endocrinology and Metabolism.2021; 36(6): 1232. CrossRef
A preliminary report about the detection of ventricular repolarisation in patients with non-alcoholic fatty liver disease
Marwan S. Al-Nimer, Vian A. Esmail, Dler S. Hamid, Mohammad O. Mohammad
Journal of Taibah University Medical Sciences.2020; 15(4): 284. CrossRef
Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation
Nattavadee Pengrattanachot, Rada Cherngwelling, Krit Jaikumkao, Anchalee Pongchaidecha, Laongdao Thongnak, Myat Theingi Swe, Varanuj Chatsudthipong, Anusorn Lungkaphin
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2020; 1866(6): 165741. CrossRef
Correlation Between Non-Alcoholic Fatty Liver and Chronic Kidney Disease
Hasyim Kasim, St. Rabiul Zatalia, Haerani Rasyid, Syakib Bakri, Muhammad L. Parewangi, Fardah Akil, Arifin Seweng
The Open Urology & Nephrology Journal.2020; 13(1): 1. CrossRef
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
Diabetes & Metabolism Journal.2020; 44(3): 382. CrossRef
Sarcopenia: an emerging risk factor for non-alcoholic fatty liver disease
Yong-ho Lee, Seung Up Kim
Hepatology International.2020; 14(1): 5. CrossRef
Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus
Hokyou Lee, Gyuri Kim, Young Ju Choi, Byung Wook Huh, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Eun Jig Lee, Yong-ho Lee, Kap Bum Huh
Diabetes & Metabolism Journal.2020; 44(2): 267. CrossRef
Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
Eugene Han, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
Journal of Clinical Medicine.2020; 9(1): 259. CrossRef
Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study
Hyeok-Hee Lee, Yongin Cho, Young Ju Choi, Byung Wook Huh, Byung-Wan Lee, Eun Seok Kang, Seok Won Park, Bong-Soo Cha, Eun Jig Lee, Yong-ho Lee, Kap Bum Huh
Cardiovascular Diabetology.2020;[Epub] CrossRef
Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
Medicine.2020; 99(33): e21038. CrossRef
Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west?
Min Zhang, Su Lin, Ming-fang Wang, Jiao-feng Huang, Shi-ying Liu, Su-mei Wu, Hao-yang Zhang, Zi-mu Wu, Wen-Yue Liu, Dong-Chu Zhang, Chuan-ming Hao, Yue-yong Zhu, Ming-Hua Zheng, Xiao-zhong Wang
BMC Gastroenterology.2020;[Epub] CrossRef
Association Between Serum Bilirubin and the Progression of Carotid Atherosclerosis in Type 2 Diabetes
Inkuk Lee, Hyeok-Hee Lee, Yongin Cho, Young Ju Choi, Byung Wook Huh, Byung-Wan Lee, Eun Seok Kang, Seok Won Park, Bong-Soo Cha, Eun Jig Lee, Yong-ho Lee, Kap Bum Huh
Journal of Lipid and Atherosclerosis.2020; 9(1): 195. CrossRef
Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
Chan-Hee Jung
Journal of Obesity & Metabolic Syndrome.2020; 29(2): 158. CrossRef
Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview
Niki Katsiki, Anca Pantea Stoian, Paschalis Steiropoulos, Nikolaos Papanas, Andra-Iulia Suceveanu, Dimitri P. Mikhailidis
Metabolites.2020; 10(11): 465. CrossRef
Heart Failure and Liver Disease
Andrew Xanthopoulos, Randall C. Starling, Takeshi Kitai, Filippos Triposkiadis
JACC: Heart Failure.2019; 7(2): 87. CrossRef
Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients
Asieh Mansour, Mohammad Reza Mohajeri-Tehrani, Majid Samadi, Hadis Gerami, Mostafa Qorbani, Nick Bellissimo, Hossein Poustchi, Azita Hekmatdoost
Acta Diabetologica.2019; 56(11): 1199. CrossRef
Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model
Jae-Sung Ryu, Minji Lee, Seon Ju Mun, Sin-Hyoung Hong, Ho-Joon Lee, Hyo-Suk Ahn, Kyung-Sook Chung, Gun-Hwa Kim, Myung Jin Son
Journal of Biological Engineering.2019;[Epub] CrossRef
Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment
Niki Katsiki, Vasilios G Athyros
Current Medical Research and Opinion.2019; 35(7): 1305. CrossRef
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
Yong-ho Lee, Yongin Cho, Byung-Wan Lee, Cheol-Young Park, Dae Ho Lee, Bong-Soo Cha, Eun-Jung Rhee
Diabetes & Metabolism Journal.2019; 43(1): 31. CrossRef
Progress in the Study of the Pathogenesis of Chronic Kidney Disease Associated with Nonalcoholic Fatty Liver Disease
清莲宋
Advances in Clinical Medicine.2019; 09(09): 1073. CrossRef
Association Between Nonalcoholic Fatty Liver Disease and Future Deterioration of Metabolic Health: A Cohort Study
You‐Cheol Hwang, Hong‐Yup Ahn, Cheol‐Young Park
Obesity.2019; 27(8): 1360. CrossRef
Subfornical organ insulin receptors tonically modulate cardiovascular and metabolic function
Jin Kwon Jeong, Julie A. Horwath, Hayk Simonyan, Katherine A. Blackmore, Scott D. Butler, Colin N. Young
Physiological Genomics.2019; 51(8): 333. CrossRef
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, Cheol-Young Park
Diabetes & Metabolism Journal.2019; 43(2): 127. CrossRef
Chicken Protein Hydrolysates Have Anti-Inflammatory Effects on High-Fat Diet Induced Obesity in Mice
Thomas Aloysius, Ana Carvajal, Rasa Slizyte, Jon Skorve, Rolf Berge, Bodil Bjørndal
Medicines.2018; 6(1): 5. CrossRef
STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia
Emmelie Cansby, Elin Magnusson, Esther Nuñez-Durán, Manoj Amrutkar, Matteo Pedrelli, Paolo Parini, Jenny Hoffmann, Marcus Ståhlman, Brian W. Howell, Hanns-Ulrich Marschall, Jan Borén, Margit Mahlapuu
Arteriosclerosis, Thrombosis, and Vascular Biology.2018; 38(8): 1723. CrossRef
Organ-Specific Mechanisms of Transendothelial Neutrophil Migration in the Lung, Liver, Kidney, and Aorta
Sanne L. Maas, Oliver Soehnlein, Joana R. Viola
Frontiers in Immunology.2018;[Epub] CrossRef
Visceral adiposity index as a predictor of NAFLD: A prospective study with 4‐year follow‐up
Chaonan Xu, Zhimin Ma, Yunfeng Wang, Xiangtong Liu, Lixin Tao, Deqiang Zheng, Xiuhua Guo, Xinghua Yang
Liver International.2018; 38(12): 2294. CrossRef
Obesity induced alterations in redox homeostasis and oxidative stress are present from an early age
Alfonso M. Lechuga-Sancho, David Gallego-Andujar, Pablo Ruiz-Ocaña, Francisco M. Visiedo, Ana Saez-Benito, Mónica Schwarz, Carmen Segundo, Rosa M. Mateos, Manuel Portero-Otin
PLOS ONE.2018; 13(1): e0191547. CrossRef
Capybara Oil Improves Hepatic Mitochondrial Dysfunction, Steatosis, and Inflammation in a Murine Model of Nonalcoholic Fatty Liver Disease
Polyana C. Marinho, Aline B. Vieira, Priscila G. Pereira, Kíssila Rabelo, Bianca T. Ciambarella, Ana L. R. Nascimento, Erika Cortez, Aníbal S. Moura, Fernanda V. Guimarães, Marco A. Martins, Gonzalo Barquero, Rodrigo N. Ferreira, Jorge J. de Carvalho
Evidence-Based Complementary and Alternative Medicine.2018; 2018: 1. CrossRef
Persistently Increased Resting Energy Expenditure Predicts Short-Term Mortality in Patients with Acute-on-Chronic Liver Failure
Jia Yao, Xiaoshuang Zhou, Hui Wang, Lili Yuan, Yu Chen, Zhongping Duan
Annals of Nutrition and Metabolism.2018; 73(1): 2. CrossRef
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice
Dong Wang, Yuhuan Luo, Xiaoxin Wang, David Orlicky, Komuraiah Myakala, Pengyuan Yang, Moshe Levi
International Journal of Molecular Sciences.2018; 19(1): 137. CrossRef
Association of sex hormone-binding globulin with nonalcoholic fatty liver disease in Chinese adults
Jing Luo, Qian Chen, Tianran Shen, Xu Wang, Wanjun Fang, Xiaocai Wu, Zenan Yuan, Gengdong Chen, Wenhua Ling, Yuming Chen
Nutrition & Metabolism.2018;[Epub] CrossRef

Original Article

Higher Glycated Hemoglobin Level Is Associated with Increased Risk for Ischemic Stroke in Non-Diabetic Korean Male Adults: Hyung Geun Oh, Eun-Jung Rhee, Tae-Woong Kim, Kyung Bok Lee, Jeong-Ho Park, Kwang-Ik Yang, Dushin Jeong, Hyung-Kook Park; Diabetes Metab J. 2011;35(5):551-557. Published online October 31, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.5.551

4,176 View
57 Download
14 Crossref

Abstract PDF PubReader

Background

The role of glycated hemoglobin (HbA1c) in the prediction of ischemic stroke in non-diabetic subjects is not clear. We performed a study to analyze the role of HbA1c in the risk prediction of ischemic stroke in non-diabetic Korean males adult.

Methods

A total of 307 non-diabetic male patients with ischemic stroke were enrolled, and 253 age-matched control subjects without a history of diabetes, hypertension, or cardiovascular disease were selected from a Health Check-up database. Anthropometric measurement data, fasting glucose level, lipid profile, and HbA1c level were available for all subjects. Associations of the variables and the presence or absence of ischemic stroke were analyzed.

Results

The ischemic stroke patient group had significantly higher HbA1c levels (5.8±0.5% vs. 5.5±0.5%, P<0.01) and mean systolic and diastolic blood pressure compared with the control group. Among the variables, smoking, low high density lipoprotein cholesterol, systolic blood pressure, and HbA1c were the significant determinants for ischemic stroke. The highest quartile of HbA1c showed a 9.6-fold increased odds ratio for ischemic stroke compared with the lowest quartile of HbA1c (odds ratio, 9.596; 95% confidence interval, 3.859 to 23.863, P<0.01). The proportion of ischemic stroke patients showed a significant trend for increment as the deciles of HbA1c increased (P for trend <0.01).

Conclusion

Higher HbA1c indicated a significantly increased risk for ischemic stroke after adjusting for other confounding variables in non-diabetic Korean adult males. HbA1c might have significance in predicting the risk for ischemic stroke even in the non-diabetic range.

Citations

Citations to this article as recorded by

Association of Glycated Hemoglobin With Acute Ischemic Stroke in a Tertiary Care Center in a Tribal Region of Jharkhand
Shimpy Priya, Vikas Mardi, Siddharth Kapoor, Abhay Kumar, Usha Saroj, Ajit Dungdung, Raunak Rishu
Cureus.2024;[Epub] CrossRef
Machine learning algorithms identify demographics, dietary features, and blood biomarkers associated with stroke records
Jundong Liu, Elizabeth L. Chou, Kui Kai Lau, Peter Y.M. Woo, Jun Li, Kei Hang Katie Chan
Journal of the Neurological Sciences.2022; 440: 120335. CrossRef
HbA1c and clinical outcomes after endovascular treatment in patients with posterior circulation large vessel occlusion: a subgroup analysis of a nationwide registry (BASILAR)
Feixue Yue, Zhongxiu Wang, Jie Pu, Min Zhang, Yong Liu, Hongxing Han, Wenhua Liu, Xianjun Wang, Rongzong Li, Dongzhang Xue, Jiaming Cao, Zhizhong Yan, Guozhong Niu, Hao Zhang, Haitao Guan, Hongliang Zeng, Feng You, Qian Yang, Wenjie Zi, Yi Zhang, Zetao Sh
Therapeutic Advances in Neurological Disorders.2020; 13: 175628642098135. CrossRef
Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study
Jorge Navarro-Pérez, Domingo Orozco-Beltran, Vicente Gil-Guillen, Vicente Pallares, Francisco Valls, Antonio Fernandez, Ana María Perez-Navarro, Carlos Sanchis, Alejandro Dominguez-Lucas, Jose M. Martin-Moreno, Josep Redon, Maria Tellez-Plaza
BMC Cardiovascular Disorders.2018;[Epub] CrossRef
Hemoglobin A1c and risk of left atrial thrombus and spontaneous echo contrast in non-valvular atrial fibrillation patients
Rong-Ren Kuang, Fang-Zhou Liu, Yun-Peng Li, Wei-Dong Lin, Hua-Sheng Liang, Ai-Hua Chen
European Journal of Medical Research.2017;[Epub] CrossRef
Early New Ischemic Lesions Located Outside the Initially Affected Vascular Territory Appear More Often in Stroke Patients with Elevated Glycated Hemoglobin (HbA1c)
Tim Bastian Braemswig, Christian H. Nolte, Jochen B. Fiebach, Tatiana Usnich
Frontiers in Neurology.2017;[Epub] CrossRef
Blood Pressure Is the Determinant for the Increased Risk for Intracranial Arterial Stenosis in Subjects with Elevated Glycated Hemoglobin Levels: The Kangbuk Samsung Health Study
Hyung-Geun Oh, Eun-Jung Rhee
Journal of Stroke and Cerebrovascular Diseases.2016; 25(11): 2729. CrossRef
Prognosis of Ischemic Stroke With Newly Diagnosed Diabetes Mellitus According to Hemoglobin A1c Criteria in Chinese Population
Jing Jing, Yuesong Pan, Xingquan Zhao, Huaguang Zheng, Qian Jia, Hao Li, Ling Guan, Liping Liu, Chunxue Wang, Xia Meng, Yan He, Yilong Wang, Yongjun Wang
Stroke.2016; 47(8): 2038. CrossRef
The Impact of Diabetes Mellitus and Corresponding HbA1c Levels on the Future Risks of Cardiovascular Disease and Mortality: A Representative Cohort Study in Taiwan
Yun-Yu Chen, Yenn-Jiang Lin, Eric Chong, Pei-Chun Chen, Taz-Fan Chao, Shih-Ann Chen, Kuo-Liong Chien, An Pan
PLOS ONE.2015; 10(4): e0123116. CrossRef
Haptoglobin genotype modulates the relationships of glycaemic control with cognitive function in elderly individuals with type 2 diabetes
Elizabeth Guerrero-Berroa, Ramit Ravona-Springer, Anthony Heymann, James Schmeidler, Andrew Levy, Derek Leroith, Michal S. Beeri
Diabetologia.2015; 58(4): 736. CrossRef
Glycated Hemoglobin is a Better Predictor than Fasting Glucose for Cardiometabolic Risk in Non-diabetic Korean Women
So Ra Yoon, Jae Hyang Lee, Ga Yoon Na, Yu Jeong Seo, Seongho Han, Min-Jeong Shin, Oh Yoen Kim
Clinical Nutrition Research.2015; 4(2): 97. CrossRef
Assessment of the Association between Mean Hemoglobin A1c Levels for 5 Years and Coronary Artery Disease by Coronary Angiography in Nondiabetic Patients
Jae-Joon Kim, Ji-Hoon Kang, Ja-Jun Goo, Kyoung-Nyoun Kim, Ja-Young Lee, Mi-kyung Kim, Tae Ik Kim
Diabetes & Metabolism Journal.2014; 38(1): 58. CrossRef
Glycated Hemoglobin and All-Cause and Cause-Specific Mortality in Singaporean Chinese Without Diagnosed Diabetes: The Singapore Chinese Health Study
Michael P. Bancks, Andrew O. Odegaard, James S. Pankow, Woon-Puay Koh, Jian-Min Yuan, Myron D. Gross, Mark A. Pereira
Diabetes Care.2014; 37(12): 3180. CrossRef
Letter: Higher Glycated Hemoglobin Level Is Associated with Increased Risk of Ischemic Stroke in Non-Diabetic Korean Male Adults (Diabetes Metab J 2011;35:551-7)
Seok Hong Lee, Jihyun Ahn, Jaetaek Kim
Diabetes & Metabolism Journal.2012; 36(1): 79. CrossRef

First
Prev
Page of 1
Next
Last

Search